Emilio Bria

15.6k total citations · 1 hit paper
392 papers, 7.1k citations indexed

About

Emilio Bria is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Emilio Bria has authored 392 papers receiving a total of 7.1k indexed citations (citations by other indexed papers that have themselves been cited), including 257 papers in Oncology, 201 papers in Pulmonary and Respiratory Medicine and 100 papers in Cancer Research. Recurrent topics in Emilio Bria's work include Lung Cancer Treatments and Mutations (117 papers), Lung Cancer Research Studies (63 papers) and Cancer Treatment and Pharmacology (56 papers). Emilio Bria is often cited by papers focused on Lung Cancer Treatments and Mutations (117 papers), Lung Cancer Research Studies (63 papers) and Cancer Treatment and Pharmacology (56 papers). Emilio Bria collaborates with scholars based in Italy, United States and Malaysia. Emilio Bria's co-authors include Giampaolo Tortora, Michèle Milella, Sara Pilotto, Diana Giannarelli, Francesco Cognetti, Isabella Sperduti, Federica Cuppone, E. Terzoli, Paolo Carlini and Luisa Carbognin and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Emilio Bria

367 papers receiving 7.0k citations

Hit Papers

Differential Activity of Nivolumab, Pembrolizumab and MPD... 2015 2026 2018 2022 2015 100 200 300
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers
    2015 375 citations Luisa Carbognin, Sara Pilotto et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emilio Bria Italy 46 4.0k 2.8k 1.8k 1.5k 953 392 7.1k
Thomas Muley Germany 47 2.9k 0.7× 4.2k 1.5× 2.4k 1.3× 1.5k 1.0× 892 0.9× 231 8.5k
Boštjan Šeruga Canada 34 4.4k 1.1× 1.8k 0.6× 1.2k 0.7× 1.6k 1.1× 809 0.8× 124 7.4k
Judith R. Kroep Netherlands 45 3.1k 0.8× 1.8k 0.6× 1.6k 0.9× 1.5k 1.0× 695 0.7× 215 7.0k
Tae‐You Kim South Korea 48 4.3k 1.1× 2.5k 0.9× 2.0k 1.1× 1.5k 1.0× 1.0k 1.1× 189 7.6k
Nick Pavlakis Australia 45 4.9k 1.2× 3.5k 1.2× 1.9k 1.1× 1.6k 1.0× 995 1.0× 307 8.6k
Rossana Berardi Italy 45 4.2k 1.1× 2.8k 1.0× 1.9k 1.1× 1.4k 0.9× 1.1k 1.2× 344 7.4k
Antônio Rossi Italy 45 3.9k 1.0× 3.8k 1.3× 2.3k 1.3× 1.1k 0.7× 1.1k 1.1× 365 8.3k
Jee Hyun Kim South Korea 43 5.2k 1.3× 2.9k 1.0× 1.5k 0.9× 1.4k 0.9× 1.8k 1.9× 320 8.1k
Martin J. Edelman United States 52 4.6k 1.2× 4.3k 1.5× 2.0k 1.1× 946 0.6× 1.0k 1.1× 302 8.7k
Gérard Zalcman France 39 3.5k 0.9× 3.0k 1.1× 2.1k 1.2× 890 0.6× 539 0.6× 299 6.7k

Countries citing papers authored by Emilio Bria

Since Specialization
Citations

This map shows the geographic impact of Emilio Bria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emilio Bria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emilio Bria more than expected).

Fields of papers citing papers by Emilio Bria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emilio Bria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emilio Bria. The network helps show where Emilio Bria may publish in the future.

Co-authorship network of co-authors of Emilio Bria

This figure shows the co-authorship network connecting the top 25 collaborators of Emilio Bria. A scholar is included among the top collaborators of Emilio Bria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emilio Bria. Emilio Bria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chiappetta, Marco, Elisa De Paolis, Dania Nachira, et al.. (2025). The Role of ctDNA for Diagnosis and Histological Prediction in Early Stage Non-Small-Cell Lung Cancer: A Narrative Review. Diagnostics. 15(7). 904–904. 3 indexed citations
2.
Vita, Emanuele, Armando Orlandi, Gennaro Daniele, et al.. (2024). The likelihood of being helped or harmed as a patient-centred tool to assess ALK-Inhibitors clinical impact and safety in ALK-addicted non-small cell lung cancer: A systematic review and sensitivity-analysis. Cancer Treatment and Research Communications. 41. 100842–100842. 3 indexed citations
3.
Bria, Emilio, José Luís Costa, Claudio Sini, et al.. (2024). 1283P Advanced ALK-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns and outcomes from the Italian biomarker ATLAS database. Annals of Oncology. 35. S818–S818. 1 indexed citations
4.
Belluomini, Lorenzo, Alice Avancini, Marco Sposito, et al.. (2024). Integrating nutrition, physical exercise, psychosocial support and antiemetic drugs into CINV management: The road to success. Critical Reviews in Oncology/Hematology. 201. 104444–104444. 4 indexed citations
5.
Pérol, M., Kōichi Goto, Benjamin Solomon, et al.. (2024). Intracranial outcomes of 1L selpercatinib in advanced RET fusion-positive NSCLC: LIBRETTO-431 study.. Journal of Clinical Oncology. 42(16_suppl). 8547–8547.
6.
Pérol, M., Benjamin Solomon, Kōichi Goto, et al.. (2024). CNS Protective Effect of Selpercatinib in First-Line RET Fusion-Positive Advanced Non–Small Cell Lung Cancer. Journal of Clinical Oncology. 42(21). 2500–2505. 5 indexed citations
7.
Ferrara, Miriam Grazia, Lorenzo Belluomini, Marco Sposito, et al.. (2023). Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors. Critical Reviews in Oncology/Hematology. 184. 103929–103929. 14 indexed citations
8.
Carbognin, Luisa, E. Di Monte, Gaetano Arcuri, et al.. (2023). 138P Activity and efficacy of neoadjuvant chemotherapy (NACT) in luminal-HER2-negative early breast cancer (EBC) according to HER2 score (low vs score 0): A retrospective study. ESMO Open. 8(1). 101477–101477. 1 indexed citations
9.
Lococo, Filippo, Alessandra Cancellieri, Marco Chiappetta, et al.. (2023). Salvage Surgery After First-Line Alectinib for Locally-Advanced/Metastatic ALK-Rearranged NSCLC: Pathological Response and Perioperative Results. Clinical Lung Cancer. 24(5). 467–473. 4 indexed citations
10.
Calegari, Maria Alessandra, Michele A. Basso, Lisa Salvatore, et al.. (2023). Maintenance strategies after anti-EGFR-based induction in metastatic colorectal cancer: A systematic review and bayesian network meta-analysis. Critical Reviews in Oncology/Hematology. 191. 104106–104106. 4 indexed citations
11.
Sposito, Marco, Lorenzo Belluomini, Daniela Tregnago, et al.. (2023). Adjuvant Targeted Therapy in Solid Cancers: Pioneers and New Glories. Journal of Personalized Medicine. 13(10). 1427–1427. 2 indexed citations
12.
Agnes, S., Armando Orlandi, George L. Clarke, et al.. (2022). Prognostic Factors in Patients with Breast Cancer Liver Metastases Undergoing Liver Resection: Systematic Review and Meta-Analysis. Cancers. 14(7). 1691–1691. 4 indexed citations
13.
Γκουντάκος, Αναστάσιος, Giovanni Centonze, Emanuele Vita, et al.. (2022). Identification of Targetable Liabilities in the Dynamic Metabolic Profile of EGFR-Mutant Lung Adenocarcinoma: Thinking beyond Genomics for Overcoming EGFR TKI Resistance. Biomedicines. 10(2). 277–277. 10 indexed citations
14.
Bazzichetto, Chiara, Michèle Milella, Francesca Simionato, et al.. (2022). Interleukin-8 in Colorectal Cancer: A Systematic Review and Meta-Analysis of Its Potential Role as a Prognostic Biomarker. Biomedicines. 10(10). 2631–2631. 19 indexed citations
15.
Cencioni, Chiara, Ilaria Trestini, Geny Piro, et al.. (2022). Gastrointestinal Cancer Patient Nutritional Management: From Specific Needs to Novel Epigenetic Dietary Approaches. Nutrients. 14(8). 1542–1542. 25 indexed citations
16.
Passaro, Antonio, Silvia Novello, Diana Giannarelli, et al.. (2021). Early Progression in Non-Small Cell Lung Cancer (NSCLC) with High PD-L1 Treated with Pembrolizumab in First-Line Setting: A Prognostic Scoring System Based on Clinical Features. Cancers. 13(12). 2935–2935. 14 indexed citations
17.
Strippoli, Antonia, Alessandra Cocomazzi, Michele Basso, et al.. (2020). c-MYC Expression Is a Possible Keystone in the Colorectal Cancer Resistance to EGFR Inhibitors. Cancers. 12(3). 638–638. 57 indexed citations
18.
Ferrara, Miriam Grazia, Vincenzo Di Noia, Ettore D’Argento, et al.. (2020). Oncogene-Addicted Non-Small-Cell Lung Cancer: Treatment Opportunities and Future Perspectives. Cancers. 12(5). 1196–1196. 63 indexed citations
19.
Simbolo, Michele, Caterina Vicentini, Andrea Ruzzenente, et al.. (2018). Genetic alterations analysis in prognostic stratified groups identified TP53 and ARID1A as poor clinical performance markers in intrahepatic cholangiocarcinoma. Scientific Reports. 8(1). 7119–7119. 36 indexed citations
20.
Trestini, Ilaria, Luisa Carbognin, Alessandro De Toma, et al.. (2018). Clinical implication of changes in body composition and weight in patients with early-stage and metastatic breast cancer. Critical Reviews in Oncology/Hematology. 129. 54–66. 38 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Thomas Muley Breakdown of academic impact, for papers by Boštjan Šeruga Breakdown of academic impact, for papers by Judith R. Kroep Breakdown of academic impact, for papers by Tae‐You Kim Breakdown of academic impact, for papers by Nick Pavlakis Breakdown of academic impact, for papers by Rossana Berardi Breakdown of academic impact, for papers by Antônio Rossi Breakdown of academic impact, for papers by Jee Hyun Kim Breakdown of academic impact, for papers by Martin J. Edelman Breakdown of academic impact, for papers by Gérard Zalcman
Rankless by CCL
2026